Welcome to our dedicated page for Elicio Therapeutics news (Ticker: ELTX), a resource for investors and traders seeking the latest updates and insights on Elicio Therapeutics stock.
Elicio Therapeutics, Inc. (ELTX) is a clinical-stage biotechnology company pioneering lymph node-targeted immunotherapies through its proprietary AMP platform. This dedicated news hub provides investors and industry observers with timely updates on ELTX's progress in developing novel cancer treatments.
Access official press releases, clinical trial milestones, and corporate developments related to ELTX's innovative pipeline. Track updates on KRAS-targeted vaccines, AMP platform advancements, and strategic collaborations. Our curated collection includes regulatory filings, peer-reviewed research highlights, and financial disclosures essential for informed analysis.
Key focus areas include clinical progress updates, partnership announcements, intellectual property developments, and scientific presentations. This resource serves investors seeking to monitor ELTX's position in the competitive immunotherapy landscape while staying informed about its novel approach to enhancing T cell responses against aggressive cancers.
Bookmark this page for streamlined access to verified ELTX developments. Check regularly for updates on the company's mission to transform cancer treatment through precision immune system engagement.
Elicio Therapeutics (NASDAQ:ELTX) announced updated Phase 1 AMPLIFY-201 follow-up data for ELI-002 published in Nature Medicine. At 19.7 months median follow-up, the study showed significant improvements in survival metrics for minimal residual disease-positive, adjuvant-stage patients.
Key findings include median overall survival increasing to 28.94 months from 16.33 months, with patients showing T cell responses above threshold experiencing a 77% reduction in death risk and 88% reduction in relapse risk. The treatment demonstrated strong efficacy with 84% of patients showing mKRAS-specific T cell responses and tumor biomarker responses.
The final disease-free survival analysis for the Phase 2 AMPLIFY-7P study in pancreatic ductal adenocarcinoma is expected in Q4 2025. The therapy was well-tolerated with no safety concerns or dose-limiting toxicities reported.
Elicio Therapeutics (NASDAQ:ELTX) reported Q2 2025 financial results and provided updates on its cancer immunotherapy pipeline. The Independent Data Monitoring Committee (IDMC) recommended continuing the ELI-002 7P Phase 2 study in pancreatic cancer without modifications, with final disease-free survival (DFS) analysis expected in Q4 2025.
Financial highlights include a $10 million non-dilutive financing secured in June 2025. Q2 2025 showed R&D expenses of $7.0 million (down from $8.2M in Q2 2024) and a net loss of $10.6 million. Cash position of $22.1 million is expected to fund operations into Q1 2026, beyond the anticipated Phase 2 final analysis.
The company plans to request an End-of-Phase 2 FDA meeting to finalize the regulatory strategy for ELI-002's pivotal Phase 3 trial following the final DFS analysis.
Elicio Therapeutics (NASDAQ:ELTX) announced that the Independent Data Monitoring Committee (IDMC) has recommended continuing the Phase 2 AMPLIFY-7P study of ELI-002 7P for pancreatic cancer without modifications. The trial, involving 144 patients across 24 U.S. sites, evaluates ELI-002 7P's effectiveness against standard of care in improving disease-free survival (DFS) for pancreatic ductal adenocarcinoma (PDAC) patients.
The IDMC's positive recommendation suggests preliminary efficacy signals and confirms a favorable safety profile. The final DFS analysis is expected in Q4 2025. Notably, Elicio has already aligned with the FDA on key elements of the planned Phase 3 study design and maintains a cash runway extending into Q1 2026.
Elicio Therapeutics (NASDAQ: ELTX) reported its Q1 2025 financial results and provided corporate updates. The company is advancing toward a crucial Phase 2 AMPLIFY-7P interim analysis expected in Q3 2025, focusing on disease-free survival in pancreatic cancer treatment. Key financial highlights include: R&D expenses of $7.8M (up from $7.6M in Q1 2024), G&A expenses of $3.0M (up from $2.7M), and a net loss of $11.2M ($0.87 per share). The company's cash position of $18.4M is expected to support operations into Q4 2025.
Notable developments include FDA alignment on key Phase 3 study design elements for ELI-002, appointment of Preetam Shah as Chief Strategy and Financial Officer, and a $10M registered direct offering. ELI-002 represents a potential breakthrough in treating mKRAS-driven tumors, particularly for pancreatic cancer patients with a 13% 5-year survival rate.
Elicio Therapeutics (Nasdaq: ELTX) has announced inducement awards for its newly appointed Chief Strategy and Financial Officer, Preetam Shah, and two other new employees. The grants were approved under the Elicio 2024 Inducement Incentive Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Dr. Shah received 191,624 stock options, while the two additional employees were granted a total of 21,000 stock options. All options are priced at $4.98 per share, matching Elicio's closing price on April 15, 2025. The options vest over four years, with 25% vesting on the first employment anniversary and the remainder vesting monthly thereafter, contingent on continued employment.
Elicio Therapeutics (NASDAQ: ELTX) reported its 2024 financial results and provided corporate updates. The company completed enrollment of 144 patients in its Phase 2 AMPLIFY-7P randomized study, with disease-free survival interim analysis expected in Q3 2025. Key financial results include:
- R&D expenses increased to $33.7M (vs $23.8M in 2023)
- G&A expenses decreased to $11.3M (vs $11.9M in 2023)
- Net loss widened to $51.9M (vs $35.2M in 2023)
- Cash position of $17.6M as of December 31, 2024
The company strengthened its position with a $10M registered direct offering in January 2025, extending operations into Q4 2025. Elicio aligned with FDA on key elements of planned ELI-002 Phase 3 study design and presented encouraging Phase 1a data showing 16.3-month median recurrence-free survival and 28.9-month median overall survival.
Elicio Therapeutics (Nasdaq: ELTX) has appointed Preetam Shah, Ph.D., MBA as Chief Strategy and Financial Officer. Dr. Shah brings extensive leadership experience from previous roles as CFO and CBO at multiple public biotech companies.
The appointment comes at a important time as Elicio approaches the disease-free survival event-driven interim analysis for its Phase 2 AMPLIFY-7P study. The company is developing ELI-002 and its Amphiphile platform for cancer immunotherapy treatments.
Dr. Shah's prior experience includes serving as CFO/CBO at Cidara Therapeutics, where he managed corporate financings and business development. He also held executive positions at Brainstorm Cell Therapeutics and investment banking roles at Barclays Capital and Canaccord Genuity. He holds a Ph.D. in microbiology and an MBA from Wharton.
Elicio Therapeutics (Nasdaq: ELTX) has announced a $10.0 million registered direct offering priced at-the-market under Nasdaq rules. The offering includes 1,261,830 shares of common stock and accompanying warrants to purchase an equal number of shares at a purchase price of $7.925 per share and warrant.
The warrants will have an exercise price of $7.80 per share, will be immediately exercisable upon issuance, and will expire after five years. The offering is expected to close around January 30, 2025, with H.C. Wainwright & Co. acting as the exclusive placement agent.
The company plans to use the net proceeds for working capital and general corporate purposes. The offering is being made through an effective shelf registration statement filed with the SEC.
FAQ
What is the current stock price of Elicio Therapeutics (ELTX)?
What is the market cap of Elicio Therapeutics (ELTX)?
